CO4810341A1 - Anticuerpo monoclonal que reconoce el oligosacarido acido sialico n-glicolilado-galactosa-glucosa en tumores malignos y composicion que lo contiene - Google Patents

Anticuerpo monoclonal que reconoce el oligosacarido acido sialico n-glicolilado-galactosa-glucosa en tumores malignos y composicion que lo contiene

Info

Publication number
CO4810341A1
CO4810341A1 CO99006716A CO99006716A CO4810341A1 CO 4810341 A1 CO4810341 A1 CO 4810341A1 CO 99006716 A CO99006716 A CO 99006716A CO 99006716 A CO99006716 A CO 99006716A CO 4810341 A1 CO4810341 A1 CO 4810341A1
Authority
CO
Colombia
Prior art keywords
monoclonal antibody
galactose
glucose
glycolylated
recognizes
Prior art date
Application number
CO99006716A
Other languages
English (en)
Inventor
Perez Adriana Carr
Herrera Zaima Mozorra
Molina Luis Enrique Fernandez
Lopez Ana Maria Vazquez
Sierra Alliette Mulet
Rodriguez Rolando Perez
Original Assignee
Centro Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro Inmunologia Molecular filed Critical Centro Inmunologia Molecular
Publication of CO4810341A1 publication Critical patent/CO4810341A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Anticuerpo monoclonal generado contra el gangliósido NGcGM3caracterizado porque reconoce específicamente la secuencia oligosacarídica Ácido siálico N-glicolilado-Galactosa-Glucosa en ganglíosidos y glicoproteínas, pertenece a la subclase IgG1 y provoca actividad citolítica de las células tumorales portadoras de dicha secuencia.Una composición farmacéutica que contiene una cantidad el anticuerpo monoclonal de las reivindicaciones de la 1 a la 3, y que contiene adicionalmente un diluente o un excipiente adecuado.Un reactivo que contiene el anticuerpo monoclonal de las reivindicaciones de la 1 a la 3, acoplado a marcadores como enzimas, cromóforos, materiales quimioluminiscentes o radionucleótidos.
CO99006716A 1998-02-05 1999-02-05 Anticuerpo monoclonal que reconoce el oligosacarido acido sialico n-glicolilado-galactosa-glucosa en tumores malignos y composicion que lo contiene CO4810341A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU1998022A CU22731A1 (es) 1998-02-05 1998-02-05 Anticuerpo monoclonal que reconoce el oligosacárido ácido siálico n´glicolilado-galactosa-glucosa (ngcneu-gal-glu) en tumores malignos y composiciones farmacéuticas que los contienen

Publications (1)

Publication Number Publication Date
CO4810341A1 true CO4810341A1 (es) 1999-06-30

Family

ID=5459215

Family Applications (1)

Application Number Title Priority Date Filing Date
CO99006716A CO4810341A1 (es) 1998-02-05 1999-02-05 Anticuerpo monoclonal que reconoce el oligosacarido acido sialico n-glicolilado-galactosa-glucosa en tumores malignos y composicion que lo contiene

Country Status (17)

Country Link
US (1) US6429295B1 (es)
EP (1) EP0972782B1 (es)
JP (1) JP4125383B2 (es)
CN (1) CN1149224C (es)
AR (1) AR013021A1 (es)
AT (1) ATE250085T1 (es)
AU (1) AU764632B2 (es)
BR (1) BR9904773A (es)
CA (1) CA2286288C (es)
CO (1) CO4810341A1 (es)
CU (1) CU22731A1 (es)
DE (1) DE69911322T2 (es)
DK (1) DK0972782T3 (es)
ES (1) ES2209391T3 (es)
MX (1) MXPA99009082A (es)
PT (1) PT972782E (es)
WO (1) WO1999040119A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1349567A4 (en) * 2000-12-08 2005-10-12 Childrens Memorial Hospital COMPOSITIONS WITH GANGLIOSIDES FOR USE IN THE TREATMENT OF SKIN DISEASES
CU23007A1 (es) * 2001-04-06 2004-12-17 Ct De Inmunologia Molecular Ct De Inmunologia Mole Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos
US20040115204A1 (en) * 2002-12-11 2004-06-17 Fanger Gary R. Antibodies to treat cancer
CA2510250A1 (en) * 2002-12-20 2004-08-12 Momenta Pharmaceuticals, Inc. Glycan markers for diagnosing and monitoring disease
CU23403A1 (es) * 2003-04-23 2009-08-04 Centro Inmunologia Molecular Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores
CU23297A1 (es) * 2004-11-16 2008-07-24 Ct De Inmunologa A Molecular Formulaciones inmunoterapã0/00uticas para la inducciã"n de autoanticuerpos bloqueadores de la uniã"n de interleucina-2 a su receptor. su uso en el tratamiento del cã ncer
CN101835319B (zh) 2009-03-13 2014-05-07 奥斯兰姆有限公司 用于电子镇流器的外壳
DK2552959T3 (en) 2010-03-26 2017-05-01 Memorial Sloan Kettering Cancer Center ANTIBODIES FOR MUC16 AND PROCEDURES FOR USE THEREOF
US20120148559A1 (en) 2010-12-01 2012-06-14 Board Of Regents The University Of Texas System Compositions and method for deimmunization of proteins
WO2012106368A2 (en) 2011-01-31 2012-08-09 The Regents Of The University Of California Methods for inhibiting prostate cancer
CU24070B1 (es) 2011-12-27 2015-01-29 Ct De Inmunología Molecular Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósidos n-glicolilados gm3 (neugcgm3)
CU24120B1 (es) 2012-03-01 2015-08-27 Ct De Inmunología Molecular Anticuerpos recombinantes con especificidad dual por los gangliósidos n-acetil gm3 y n-glicolil gm3
CN104651314B (zh) 2015-02-14 2018-06-19 百泰生物药业有限公司 获得高产稳定表达细胞克隆的方法及由此获得的抗体分子
US10722523B2 (en) 2015-03-17 2020-07-28 The Regents Of The University Of California Chemoimmunotherapy for epithelial cancer
BR112017019978A2 (pt) 2015-03-17 2018-06-19 Memorial Sloan Kettering Cancer Center anticorpo ou um fragmento de ligação com antígeno, conjugado, receptor de antígeno, cadeia, conjugado de cadeia, proteína de fusão, célula t, polinucleotídeo, vetor, célula ex vivo, método para produzir uma cadeia, método para produzir um anticorpo, composição farmacêutica, método para tratamento de câncer, glicopeptídeo, método para gerar um anticorpo
CN109721632B (zh) * 2017-10-27 2023-10-31 齐鲁制药有限公司 一种高纯度神经节苷脂gm1及其制备方法
CU20210104A7 (es) 2021-12-21 2023-07-12 Ct Inmunologia Molecular Proteínas de fusión compuestas por un anticuerpo y una muteína agonista de interleucina 2

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965198A (en) * 1985-12-24 1990-10-23 Konica Corporation Monoclonal antibody and method of manufacturing hybridoma producing the same
ATE175234T1 (de) * 1990-07-10 1999-01-15 Nippon Kokan Kk Geflügelspezifischen immunglobulin g produzierende hybridomas
CA2137638C (en) 1993-12-09 1999-07-20 Ana M. V. Lopez Anti gangliosides monoclonal antibodies and their use in the specific active immunotherapy of malignant tumors

Also Published As

Publication number Publication date
DE69911322T2 (de) 2004-07-01
PT972782E (pt) 2004-02-27
DK0972782T3 (da) 2004-02-02
CA2286288A1 (en) 1999-08-12
US6429295B1 (en) 2002-08-06
CU22731A1 (es) 2002-02-28
DE69911322D1 (de) 2003-10-23
BR9904773A (pt) 2000-03-21
EP0972782B1 (en) 2003-09-17
ATE250085T1 (de) 2003-10-15
AU764632B2 (en) 2003-08-28
EP0972782A1 (en) 2000-01-19
JP4125383B2 (ja) 2008-07-30
AU2407899A (en) 1999-08-23
AR013021A1 (es) 2000-11-22
MXPA99009082A (es) 2002-04-24
CN1256696A (zh) 2000-06-14
WO1999040119A1 (es) 1999-08-12
CN1149224C (zh) 2004-05-12
JP2001509684A (ja) 2001-07-24
CA2286288C (en) 2010-09-28
WO1999040119A9 (es) 2000-07-06
ES2209391T3 (es) 2004-06-16

Similar Documents

Publication Publication Date Title
CO4810341A1 (es) Anticuerpo monoclonal que reconoce el oligosacarido acido sialico n-glicolilado-galactosa-glucosa en tumores malignos y composicion que lo contiene
DE3372175D1 (en) Covalent conjugates of an enzyme and an antibody, and medicinal compositions containing these conjugates
ES2185705T3 (es) Proteina bifuncional, preparacion y uso.
SG96535A1 (en) Pharmaceutical composition for the treatment or prevention of a malignant tumor
BRPI0409664A (pt) anticorpo recombinante, fragmento fv de cadeia simples derivado do anticorpo monoclonal murino 14f7, linhagem celular, composição farmacêutica e reativo para a localização e identificação "in vivo" de tumores malignos
ES2102196T3 (es) Periferializacion de celulas pluripotenciales hematopoyeticas.
BR0308953A (pt) composições, proteìna, polinucleotìdeo, método de geração de uma resposta imune, método de detecção, composição farmacêutica, anticorpo ou seu fragmento, animal transgênico, hibridoma, método de fornecimento de um agente citotóxico ou agente de diagnóstico e método de inibição do crescimento de células cancerosas
DK0554356T3 (da) Monoklonalt antistof
ES8800845A1 (es) Procedimiento para preparar anticuerpos monoclonales y derivados de los mismos
PT623352E (pt) Glicoproteinas bifuncionais possuindo um complemento de carbohidrato modificado e a sua utilizacao em terapia selectiva de tumor
ES551356A0 (es) Procedimiento de preparar un antigeno relacionado con el ligamiento glicosidico derivado de celulas de cancer
ATE196609T1 (de) Radiomarkierte glukane
AU4152193A (en) Anti-DCC gene product specific monoclonal antibody
Harnett et al. Biosynthetic radiolabelling of excretions-secretions of adult male Onchocerca gibsoni
CA2141025A1 (en) Anti-mucus glycoprotein monoclonal antibody
Wang et al. Progress in the early stage diagnosis of tumor using SELDI-TOF-MS protein chip technique
Dong et al. Studies on the Mechanisms of the Apoptotic Cell Death of Target Cells Mediated by Human Monocytes
EA200000442A1 (ru) Антиидиотипические моноклональные антитела, их применение в активной иммунотерапии злокачественных опухолей и содержащие их композиции
TWI265811B (en) Extended type 1 chain glycosphingolipids as tumor-associated antigens
Zhou et al. Study of cytotoxicity of anti-CD20 monoclonal antibody against myeloma cells in vitro
EP0654269A4 (en) MEDICAL COMPOSITION FOR INHIBITING CANCER METASAS IN LIVER AND MEDICAL COMPOSITION FOR TREATING THE HEPATOMA.
TW221711B (en) N-AFP monoclonal antibody and method of preparation thereof
TH11834EX (th) แอนติบอดีสังยุค